Please login to the form below
JAK1 inhibitor
This page shows the latest JAK1 inhibitor news and features for those working in and with pharma, biotech and healthcare.
Pfizer’s Cibinqo granted FDA approval for adults with moderate-to-severe atopic dermatitis
Cibinqo is a once-daily, oral Janus kinase 1 (JAK1) inhibitor used in adult patients living with moderate-to-severe atopic dermatitis who have not yet found relief in currently available
Latest news
-
FDA fast-tracks review of Incyte’s Jakafi for chronic GVHD
A decision on the JAK1/2 inhibitor is expected by 22 June 2021, Incyte said in a statement. ... However, the JAK inhibitor plus standard-of-care failed to prevent complications in this patient group in the RUXCOVID study.
-
Novartis’ canakinumab failed to improve survival in COVID-19 study
the time it took to discharge patients from hospital following treatment with the IL-6 inhibitor. ... Novartis is also still conducting a phase 3 trial of its JAK1/2 inhibitor Jakavi (ruxolitinib) in COVID-19, with preliminary results from this study
-
Incyte’s JAK inhibitor cream clears second eczema trial
Set for regulatory filings later this year. Incyte now has a pair of positive phase 3 trials for its topical formulation of JAK1/2 inhibitor ruxolitinib in atopic dermatitis or eczema, ... The reformulation could open up a new and very large treatment
-
Vyndaqel a bright spot as Pfizer comes under pressure
Key candidates coming through late-stage development include JAK1 inhibitor abrocitinib for atopic dermatitis, a vaccine for Clostridium difficile infections, and vaccine against Clostridium difficile and Eli Lilly-partnered tanezumab, which
-
Gilead promotes Andrew Dickinson to CFO, increased M&A expected
One of these potential blockbusters is JAK1 inhibitor filgotinib, which recently reported new, long-term phase 3 clinical data in rheumatoid arthritis.
More from news
Approximately 1 fully matching, plus 29 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
Sales are projected at $1.589bn in 2024. 5. Filgotinib from Gilead/Galapagos is an oral JAK1 inhibitor in regulatory review in the US, EU and Japan for rheumatoid arthritis Overactivation ... It will face competition mainly from generic statins and PCSK9
-
European biotech: a new generation of leaders emerges
is its experimental JAK1 inhibitor filgotinib for rheumatoid arthritis.
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
Upadacitinib, from AbbVie, treats rheumatoid arthritis. Upadacitinib is an orally dosed inhibitor of an intracellular target called JAK1. ... The first-in-class inhibitor of hypoxia- inducible factor-prolyl hydroxylase, or HIFPH, was approved in December
-
Drug launches to watch in 2019
It also unveiled mid-stage data on its JAK1 inhibitor upadacitinib in atopic dermatitis, adding another clinical win to earlier successes in rheumatoid arthritis. ... t the only oral JAK inhibitor developer with its eye on that particular prize.
-
Deal Watch December 2015
Galapagos (NL). Gilead. Collaboration. licence. JAK1-selective inhibitor, filgotinib in phase II for RA and Crohn's disease . ... 825. Takeda (Respiratory). AstraZeneca. Acquisition - asset. AZ buys Takeda global respiratory business including PDE 4
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- A new era for UK-Japanese scientific research relations
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- FDA issues innovative proposal to increase nonprescription drug access
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- My journey advancing the science in pulmonary hypertension
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
- Realising the potential of omnichannel in medical communications
- College of Medicine launches Beyond Pills campaign to tackle overprescribing in UK health system
- AI is transforming pharma R&D – now it can transform pharma marketing
- J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma
- Six UK universities receive grant for research into motor neurone disease
- My journey advancing the science in pulmonary hypertension
PMHub
foxandcat.online
We help communications teams to thrive under pressure. Here at fox&cat, we help all kinds of teams to fight all...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
